Please assess the completion status of the following clinical trial:

Trial Title: Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (≥ 18 years) patients with chronic hepatitis C and detectable HCV RNA by Polymerase Chain Reaction (PCR) after completion of previous direct-acting antiviral regimen, and eligible for antiviral treatment.~Exclusion Criteria:~* Patients with decompensated cirrhosis (Child-Pugh score B and C).~* Patients with platelet count less than 50000/ mm³.~* Patients with HCC or extrahepatic malignancy.~* Pregnancy or inability to use an effective contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: SOF/VEL/VOX with RBV (Type: EXPERIMENTAL): Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: \< or \> 60 kg).~Another name: Vosevi, RBV
- Group B: SOF/VEL/VOX (Type: ACTIVE_COMPARATOR): Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).~Another name: Vosevi

Based on this trial design, predict the completion outcome and termination type (if applicable).